CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 9 enrolled
Drug / intervention
11C-ER176 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03744312
NCT03744312Phase 2Completed
CompareCT.gov

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

Columbia University·interventional·Posted Nov 16, 2018·Updated Apr 17, 2025

In Brief

A Phase 2 clinical trial evaluating 11C-ER176 and Florbetaben for Alzheimer Disease. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This study is being done to learn about inflammation in the brain of those with Alzheimer's disease (AD). The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease. Both patients (with either mild cognitive impairment (MCI) or Alzheimer's disease) and healthy controls (participants without memory complaints or impairment) will be included in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedNov 16, 2018
Enrollment StartSep 10, 2018
Primary CompletionJul 20, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.6 years ago

Interventions

11C-ER176drug

11C-ER176 sticks to parts of the brain where there is inflammation. Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease. The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.

Florbetabendrug

Florbetaben sticks to amyloid plaques, which are in the brain in Alzheimer's disease.